Clinical Chemistry and Laboratory Medicine (CCLM)
Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Editor-in-Chief: Plebani, Mario
Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.
IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition
SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238
Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside
1Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Aalst, Belgium
2Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Aalst, Belgium
3Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Aalst, Belgium
4Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Aalst, Belgium
5Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium
6Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium
7Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium
Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 47, Issue 3, Pages 248–252, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2009.065, March 2009
B-type natriuretic peptide (BNP) has emerged as a reliable biomarker in patients with congestive heart failure. The mature, biologically active B-type natriuretic peptide, BNP(1–32), is cleaved by corin from the 108 amino acid proBNP. However, in vivo as well as in vitro data demonstrated that this BNP(1–32) might be an ideal substrate for the endogenous aminopeptidase, dipeptidyl-peptidase IV (DPP IV). DPP IV removes the two amino terminal amino acids (Ser Pro) from BNP(1–32) to produce BNP(3–32), which has been detected in plasma of patients with congestive heart failure. The biological effects of BNP(3–32) remain undetermined. In cultured human cardiomyocytes and fibroblasts, equimolar concentrations of BNP(1–32) and BNP(3–32) both exert similar biological effects, as evidenced by their cGMP (cyclic guanylate monophosphate) generating capacity. However, in a canine model, intravenous BNP(3–32) infusion resulted in less natriuresis, diuresis, and vasodilation compared to intravenous infusion of BNP(1–32). The clinical relevance of these observations might be important for patients in whom the plasma BNP concentrations, measured by commercially available immunoassays, are high. Further studies exploring whether DPP IV inhibitors increase the bioavailability of BNP(1–32), delay the progression of heart failure, and increase the efficacy of exogenous administration of BNP(1–32) in decompensated heart failure are needed.
Clin Chem Lab Med 2009;47:248–52.
Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.